** Drug developer Septerna's shares SEPN.O fall 66.6% to $4.49 premarket
** Co discontinues an early-stage trial of its experimental drug for patients with a hormonal disorder called hypoparathyroidism
** In hypoparathyroidism patients, the body does not produce enough levels of a hormone that regulates calcium and phosphorus levels in the blood
** SEPN says it stopped the trial after two participants showed unexpectedly high levels of a substance called unconjugated bilirubin, which forms when red blood cells break down
** Says it will advance other drugs with distinct and unrelated chemical structures relative to the discontinued treatment
** Stock has fallen nearly 40% since its Nasdaq debut in October
(Reporting by Padmanabhan Ananthan)
((Padmanabhan.Ananthan@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。